Premium
Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia
Author(s) -
Melani Alessia,
Cipriani Sara,
Corti Francesca,
Pedata Felicita
Publication year - 2010
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05732.x
Subject(s) - dipyridamole , ischemia , medicine , rat model , anesthesia , administration (probate law) , pharmacology , cardiology , political science , law
Pharmacological therapy able to improve the cognitive performances of patients with chronic vascular pathologies currently remains unavailable. Many studies of chronic cerebral hypotension in rodents have revealed alterations in reference memory and learning. Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator. It is a potent inhibitor of platelet activation and reduces formation of thrombi in vivo . In addition, it is an antithrombotic agent used for secondary stroke prevention in combination with aspirin. Recent evidence indicates that dipyridamole has anti‐inflammatory properties. Bilateral common carotid artery occlusion (2VO) in the rat is recognized as a valid model of chronic cerebral hypotension, also defined as the “vascular cognitive impairment rat model.” Here, we report that dipyridamole reverses the impairment of spatial working memory 90 days after 2VO. This protective effect might be in relation to dipyridamole's anti‐inflammatory properties.